Clinical study of the month. The HOPE study, a two-by-two factorial clinical trial with contrasted results

Scheen, A.J.

Revue medicale de Liege 55(2): 121-124

2000


ISSN/ISBN: 0370-629X
PMID: 10769584
Document Number: 516638
The results of the HOPE ("Heart Outcomes Prevention Evaluation") study, recently published in the New England Journal of Medicine, demonstrated a highly significant cardiovascular protection by an angiotensin converting enzyme inhibitor, ramipril at a dose of 10 mg/day, after a mean follow-up of 4.5 years, but not of vitamin E supplements at a dose of 400 UI/day in high-risk patients (> 55 years old) who had evidence of vascular disease (secondary prevention) or combined diabetes mellitus and another cardiovascular risk factor (primary prevention).

Document emailed within 1 workday
Secure & encrypted payments